Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salmeterol xinafoate and fluticasone propionate inhalation vs Seretide in adult asthma
CTR20243002Phase 3Completed
- Sponsor
- Aitmei
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of salmeterol + fluticasone in asthma (2 arms), sponsored by Aitmei. Primary endpoint: Change from baseline in pre-dose FEV1 at week 4. Started Aug 2024; status: completed.
02
Drugs
salmeterol + fluticasone
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20243002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243002.